Metafora Biosystems Receives €3.2 Million from European Commission’s H2020 SME Instrument Program

Grant will allow company to launch large-scale prospective validation study of METAglut1 test to help early diagnosis of rare De Vivo disease (Glut1 deficiency syndrome) Metafora biosystems, a company developing diagnostic tests to detect abnormalities in cellular energetics, today announces that it has received a European grant of €3.2 million ($3.75M) as part of the phase 2 of the European...

More From BioPortfolio on "Metafora Biosystems Receives €3.2 Million from European Commission’s H2020 SME Instrument Program"